Story perspectives

Four Children Survive Years After T-Cell Brain Cancer Therapy

7/15/2026

Summary

Story summary

Four children treated with tumour-associated antigen T-cell therapy remain alive years after diagnosis, three showing no evidence of disease.
Researchers treated 33 pediatric brain-cancer patients with the therapy that trains T-cells to recognize three antigens before reinfusion, reporting fatigue, headache and two tumour-swelling cases possibly linked to large tumour volumes.
Two trials will test the therapy with ultrasound-mediated blood-brain-barrier opening and with antigen targeting based on each tumour’s genetic profile.

1 of 1

Story summary

Four children treated with tumour-associated antigen T-cell therapy remain alive years after diagnosis, three showing no evidence of disease.
Researchers treated 33 pediatric brain-cancer patients with the therapy that trains T-cells to recognize three antigens before reinfusion, reporting fatigue, headache and two tumour-swelling cases possibly linked to large tumour volumes.
Two trials will test the therapy with ultrasound-mediated blood-brain-barrier opening and with antigen targeting based on each tumour’s genetic profile.